Market reviews

Published on 28 April 2022

Review of the Finnish human pharmaceuticals market

Finland is the most important individual market for Orion, generating more than a quarter of the Group’s net sales. According to Pharmarket statistics (1–3/2022), the total sales of Orion’s human pharmaceuticals in January-March 2022, including both medicinal and non-medicinal products, grew by 7 per cent from the previous year.

Orion’s biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales of Orion’s reference-priced prescription drugs increased by 1 per cent due to strong volume growth while the total market fell by 5 per cent from the comparative period. The average price of reference-priced drugs in the market declined by approximately 7 per cent from the comparative period (Source: Pharmarket). The impact of constant price competition on Orion has been significant due to the Company’s broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference-priced prescription drugs and self-care products, with its market share being a quarter of the market in each.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.  

Source: Pharmarket sales statistics 1-3/2022

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.             

Source: Pharmarket sales statistics 1-3/2022